We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Rapid Point-of-Care COVID-19 Antigen Test Based on Waveguide Technology Could Deliver Results in Under Six Minutes

By HospiMedica International staff writers
Posted on 25 Feb 2021
A point-of-care COVID-19 antigen test currently under development promises to deliver results in less than six minutes by using the simple test procedure of waveguide technology.

LightDeck Diagnostics (Boulder, CO, USA) is developing the LightDeck COVID-19 Antigen Test that leverages the highly sensitive and simple test procedure of waveguide technology with cost-effective manufacturing techniques to deliver an accurate, scalable test. More...
The LightDeck antigen test will be a significantly faster alternative to the current PCR based diagnostic tests, and offer better sensitivity and specificity than the available lateral flow-based tests that require at least 15 minutes to deliver results.

LightDeck has been awarded a USD 5.65 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services (HHS), to develop the rapid antigen test to detect SARS-CoV-2.

“The LightDeck COVID-19 Antigen Test will build on the existing product platform,” said Chris Myatt, CEO and Founder of LightDeck Diagnostics. “Every minute matters when we’re dealing with infectious diseases. We believe our technology can provide an optimal solution to the current gaps in COVID-19 diagnostic testing on a national level.”

Related Links:
LightDeck Diagnostics


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.